Compendium of Cancer Genome Aberrations

Changes

GTS5:Volunteer Assignments and Opportunities (view source)

Revision as of 12:23, 25 February 2024

1,328 bytes added ,  25 February
no edit summary
Line 309: Line 309:  
!'''Date of Last Editor Review'''
 
!'''Date of Last Editor Review'''
 
!'''Notes'''
 
!'''Notes'''
 +
|-
 +
|CHAPTER 2 (GROWTH FACTOR RECEPTORS AND RELATED SIGNALLING PATHWAYS)
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 
|-
 
|-
 
|[[GTS5:Hereditary_papillary_renal_carcinoma_(MET)|Hereditary papillary renal carcinoma (MET)]]
 
|[[GTS5:Hereditary_papillary_renal_carcinoma_(MET)|Hereditary papillary renal carcinoma (MET)]]
Line 727: Line 747:  
|
 
|
 
|
 
|
 +
|-
 +
|CHAPTER 3 (OXIDATIVE STRESS RESPONSE AND METABOLISM)
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 
|-
 
|-
 
|[[GTS5:Von_Hippel-Lindau_syndrome_(VHL)|Von Hippel-Lindau syndrome (VHL)]]
 
|[[GTS5:Von_Hippel-Lindau_syndrome_(VHL)|Von Hippel-Lindau syndrome (VHL)]]
Line 771: Line 811:  
|
 
|
 
|
 
|
 +
|-
 +
|CHAPTER 4 (CELL CYCLE AND APOPTOSIS PATHWAYS)
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 
|-
 
|-
 
|[[GTS5:Li-Fraumeni_syndrome_(TP53)|Li-Fraumeni syndrome (TP53)]]
 
|[[GTS5:Li-Fraumeni_syndrome_(TP53)|Li-Fraumeni syndrome (TP53)]]
Line 837: Line 897:  
|
 
|
 
|
 
|
 +
|-
 +
|CHAPTER 5 (DNA REPAIR AND GENOMIC STABILITY)
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 
|-
 
|-
 
|[[GTS5:Lynch_Syndrome_(MLH1,_PMS2,_MSH2,_MSH6)|Lynch Syndrome (MLH1, PMS2, MSH2, MSH6)]]
 
|[[GTS5:Lynch_Syndrome_(MLH1,_PMS2,_MSH2,_MSH6)|Lynch Syndrome (MLH1, PMS2, MSH2, MSH6)]]
Line 1,090: Line 1,170:  
|
 
|
 
|
 
|
 +
|-
 +
|CHAPTER 6 (TELOMERE MAINTENANCE)
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 
|-
 
|-
 
|[[GTS5:Dyskeratosis_congenita_(DKC1,_TERT,_TERC,_TINF2,_Other_IBMFS_genes)|Dyskeratosis congenita (DKC1, TERT, TERC, TINF2, Other IBMFS genes)]]
 
|[[GTS5:Dyskeratosis_congenita_(DKC1,_TERT,_TERC,_TINF2,_Other_IBMFS_genes)|Dyskeratosis congenita (DKC1, TERT, TERC, TINF2, Other IBMFS genes)]]
Line 1,112: Line 1,212:  
|
 
|
 
|
 
|
 +
|-
 +
|CHAPTER 7 (EPIGENETIC DRIVERS AND CHROMATIN REMODELLING)
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 
|-
 
|-
 
|[[GTS5:Beckwith-Wiedemann_spectrum_(IGF2;_CDKN1C)|Beckwith-Wiedemann spectrum (IGF2; CDKN1C)]]
 
|[[GTS5:Beckwith-Wiedemann_spectrum_(IGF2;_CDKN1C)|Beckwith-Wiedemann spectrum (IGF2; CDKN1C)]]
Line 1,178: Line 1,298:  
|
 
|
 
|
 
|
 +
|-
 +
|CHAPTER 8 (RNA REGULATION)
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 
|-
 
|-
 
|[[GTS5:DICER1-related_tumour_predisposition_syndrome_(DICER1)|DICER1-related tumour predisposition syndrome (DICER1)]]
 
|[[GTS5:DICER1-related_tumour_predisposition_syndrome_(DICER1)|DICER1-related tumour predisposition syndrome (DICER1)]]
Line 1,211: Line 1,351:  
|
 
|
 
|
 
|
 +
|-
 +
|CHAPTER 9 (PROTEIN REGULATION)
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 +
|
 +
----<br />
 
|-
 
|-
 
|[[GTS5:BAP1-related_tumour_predisposition_syndrome_(BAP1)|BAP1-related tumour predisposition syndrome (BAP1)]]
 
|[[GTS5:BAP1-related_tumour_predisposition_syndrome_(BAP1)|BAP1-related tumour predisposition syndrome (BAP1)]]
Retrieved from "https://ccga.io/index.php/Special:MobileDiff/14222"